Cepheid (CPHD) Announces Expanded CDT Gene Presence with Leading C. Difficile Test
- Wall Street falls with financials, other post-election gainers
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
- After-Hours Stock Movers 01/17: (SHLO) Higher; (GIMO) (AFAM) (CSX) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Particularly perilous Clostridium difficile strains are now potentially easier to detect, thanks to expanded reporting of binary toxin (CDT) gene presence with the leading molecular test for C. difficile from Cepheid (Nasdaq: CPHD).
The presence of binary toxin-producing C. difficile has been linked to increased disease severity, mortality and disease recurrence.1,2 In addition, strains of C. difficile have been documented that appear to cause disease when they are negative for the well known toxins A and B but positive for binary toxin.3,4 With the addition of Xpert C. difficile BT, Cepheid continues to offer one of the most comprehensive molecular C. difficile test portfolios on the market.
"Binary toxin (CDT) is associated with more severe C. difficile infection (CDI)," says Thomas V. Riley, Ph.D. and Microbiology Professor at The University of Western Australia. "In addition, CDT has been linked to an increase in the prevalence of community-acquired CDI, a high rate of recurrent CDI, and the need for hospital admission due to reinfection3. The detection of strains of C. difficile with the ability to produce CDT will provide valuable prognostic information."
"Recent studies indicate that some patients with suspected C. difficile harbor binary toxin producing strains that do not carry the genes for toxins A and B4," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "While the clinical significance of such strains is not yet fully understood, the vast majority of current C. difficile tests will miss these cases completely. Xpert C. difficile BT reports binary toxin status independently, which allows for detection of a wider range of hypervirulent strains and tracking of novel variants that are negative for toxins A and B."
C. difficile infection is the result of C. difficile bacteria overgrowth, commonly caused through exposure to antibiotics for treatments of other illnesses. Binary toxin is produced by a number of C. difficile strains, including PCR-ribotype 027 (Nap1/BI) and other strains associated with severe outcomes.
Xpert C. difficile BT is Cepheid's current Xpert C. difficile test, with modified result reporting that makes the additional information on the presence of binary toxin available. Xpert C. difficile BT is available immediately in countries accepting the CE-mark.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualcomm (QCOM) Responds to FTC Antitrust Charges
- EPAM Systems (EPAM), UBS Sign Strategic Multi-Year Agreement
- TopBuild (BLD) Announces Acquisition of Midwest Fireproofing
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!